Peak Asset Management’s Pfizer PFE Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $715K | Buy |
29,704
+13,017
| +78% | +$341K | 0.11% | 99 |
|
|
2026
Q1 | $469K | Sell |
16,687
-9,624
| -37% | -$256K | 0.08% | 99 |
|
|
2025
Q4 | $655K | Hold |
26,311
| – | – | 0.11% | 86 |
|
|
2025
Q3 | $670K | Sell |
26,311
-2,457
| -9% | -$60.6K | 0.12% | 84 |
|
|
2025
Q2 | $697K | Buy |
28,768
+402
| +1% | +$9.38K | 0.13% | 79 |
|
|
2025
Q1 | $719K | Buy |
28,366
+2
| +0% | +$52 | 0.14% | 79 |
|
|
2024
Q4 | $753K | Buy |
28,364
+2
| +0% | +$54 | 0.14% | 79 |
|
|
2024
Q3 | $821K | Buy |
28,362
+1
| +0% | +$29 | 0.15% | 78 |
|
|
2024
Q2 | $794K | Sell |
28,361
-1,958
| -6% | -$53.9K | 0.16% | 77 |
|
|
2024
Q1 | $841K | Buy |
30,319
+2
| +0% | +$55 | 0.17% | 81 |
|
|
2023
Q4 | $873K | Sell |
30,317
-2,644
| -8% | -$79.9K | 0.19% | 77 |
|
|
2023
Q3 | $1.09M | Sell |
32,961
-400
| -1% | -$14.1K | 0.26% | 72 |
|
|
2023
Q2 | $1.22M | Buy |
33,361
+1
| +0% | +$39 | 0.28% | 66 |
|
|
2023
Q1 | $1.36M | Sell |
33,360
-999
| -3% | -$43.1K | 0.33% | 63 |
|
|
2022
Q4 | $1.76M | Sell |
34,359
-811
| -2% | -$38.9K | 0.46% | 47 |
|
|
2022
Q3 | $1.54M | Buy |
35,170
+107
| +0.3% | +$5.2K | 0.44% | 49 |
|
|
2022
Q2 | $1.84M | Sell |
35,063
-80
| -0.2% | -$4.08K | 0.5% | 44 |
|
|
2022
Q1 | $1.82M | Sell |
35,143
-910
| -3% | -$47.2K | 0.42% | 46 |
|
|
2021
Q4 | $2.13M | Sell |
36,053
-238
| -0.7% | -$11.8K | 0.49% | 42 |
|
|
2021
Q3 | $1.56M | Sell |
36,291
-800
| -2% | -$35.4K | 0.38% | 48 |
|
|
2021
Q2 | $1.45M | Buy |
37,091
+1,528
| +4% | +$59.4K | 0.36% | 48 |
|
|
2021
Q1 | $1.29M | Sell |
35,563
-937
| -3% | -$33.3K | 0.31% | 59 |
|
|
2020
Q4 | $1.34M | Sell |
36,500
-2,535
| -6% | -$93K | 0.35% | 53 |
|
|
2020
Q3 | $1.36M | Buy |
39,035
+640
| +2% | +$22.4K | 0.41% | 51 |
|
|
2020
Q2 | $1.19M | Buy |
38,395
+8,687
| +29% | +$295K | 0.38% | 47 |
|
|
2020
Q1 | $920K | Sell |
29,708
-3,237
| -10% | -$110K | 0.35% | 47 |
|
|
2019
Q4 | $1.23M | Buy |
32,945
+36
| +0.1% | +$1.28K | 0.37% | 50 |
|
|
2019
Q3 | $1.12M | Hold |
32,909
| – | – | 0.37% | 50 |
|
|
2019
Q2 | $1.35M | Sell |
32,909
-1,054
| -3% | -$41.9K | 0.44% | 45 |
|
|
2019
Q1 | $1.37M | Sell |
33,963
-1,263
| -4% | -$50.6K | 0.47% | 44 |
|
|
2018
Q4 | $1.46M | Hold |
35,226
| – | – | 0.55% | 43 |
|
|
2018
Q3 | $1.47M | Sell |
35,226
-543
| -2% | -$20.9K | 0.5% | 43 |
|
|
2018
Q2 | $1.23M | Sell |
35,769
-3,383
| -9% | -$116K | 0.45% | 42 |
|
|
2018
Q1 | $1.32M | Sell |
39,152
-1,941
| -5% | -$66.7K | 0.48% | 43 |
|
|
2017
Q4 | $1.41M | Sell |
41,093
-1,265
| -3% | -$43.1K | 0.52% | 42 |
|
|
2017
Q3 | $1.44M | Sell |
42,358
-3,162
| -7% | -$102K | 0.51% | 45 |
|
|
2017
Q2 | $1.45M | Buy |
45,520
+9,453
| +26% | +$298K | 0.54% | 44 |
|
|
2017
Q1 | $1.17M | Sell |
36,067
-1,370
| -4% | -$43.2K | 0.44% | 50 |
|
|
2016
Q4 | $1.15M | Buy |
37,437
+316
| +0.9% | +$9.65K | 0.46% | 50 |
|
|
2016
Q3 | $1.19M | Sell |
37,121
-279
| -0.7% | -$9.33K | 0.5% | 50 |
|
|
2016
Q2 | $1.25M | Buy |
37,400
+158
| +0.4% | +$5.04K | 0.55% | 47 |
|
|
2016
Q1 | $1.05M | Hold |
37,242
| – | – | 0.5% | 44 |
|
|
2015
Q4 | $1.14M | Buy |
37,242
+7,320
| +24% | +$230K | 0.56% | 40 |
|
|
2015
Q3 | $892K | Buy |
29,922
+2,066
| +7% | +$66.2K | 0.48% | 44 |
|
|
2015
Q2 | $886K | Buy |
27,856
+1,202
| +5% | +$39.2K | 0.46% | 46 |
|
|
2015
Q1 | $880K | Buy |
26,654
+203
| +0.8% | +$6.45K | 0.44% | 45 |
|
|
2014
Q4 | $782K | Buy |
+26,451
| New | +$758K | 0.41% | 48 |
|
Other funds holding PFE
Peak Asset Management's PFE Position: Q2 2026 in Review
Peak Asset Management increased its Pfizer (PFE) stake by 78% in Q2 2026, buying an estimated $341K and bringing the position to 29,704 shares worth $715K. The position accounts for 0.11% of the portfolio, ranked #99.
Peak Asset Management first reported a position in PFE in Q4 2014 and has held it in 47 quarters since. The position peaked at $2.13M in Q4 2021. 2,822 funds tracked by Wall St. Rank hold PFE as of Q2 2026.
- Peak Asset Management held 29,704 shares of Pfizer worth $715K as of Q2 2026.
- Peak Asset Management bought 13,017 Pfizer shares in Q2 2026, an estimated $341K.
- Pfizer made up 0.11% of Peak Asset Management's portfolio in Q2 2026, its #99 holding.
- Peak Asset Management first reported a position in Pfizer in Q4 2014 and has held it in 47 quarters since.
- Peak Asset Management's Pfizer position peaked at $2.13M in Q4 2021.
- 2,822 funds tracked by Wall St. Rank held Pfizer as of Q2 2026.
Based on Peak Asset Management's 13F filing for Q2 2026, filed 14 Aug 2026.